TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Comprehensive valuation analysis, historical median multiples, earnings yield, and sector peer benchmarking.
Anuh Pharma Limited trades at 20.41x P/E compared to its estimated 3-year median of 19.39x. This represents a 5.3% premium to its multi-year historical trading baseline.
Compared to the wider Biotechnology & Drugs peer group median of 24.50x, ANUHPHR is trading at a 16.7% discount.
| Company | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|
| ★ Anuh Pharma LimitedActive | 20.41 | 2.38 | 0 |
| AstraZeneca Pharma India Limited(ASTRAZEN) | — | — | 0.002 |
| Alembic Limited(ALEMBICLTD) | 8.09 | 1.05 | 0 |
| Amrutanjan Health Care Limited(AMRUTANJAN) | 25.67 | 4.02 | 0 |
| Bajaj Healthcare Limited(BAJAJHCARE) | 47.93 | 2.03 | 0 |
| Anlon Healthcare Limited(AHCL) | 26.55 | 3.67 | 0 |
Anuh Pharma Limited (ANUHPHR) currently trades at a Price-to-Earnings (P/E) multiple of 20.41 based on its latest reported trailing-twelve-month (TTM) earnings.
Anuh Pharma Limited's current P/E of 20.41 compares to its 3-year median P/E of 19.39 (+5.3% premium) and 5-year median P/E of 18.37.
Anuh Pharma Limited operates in the Biotechnology & Drugs sector, where the sector median P/E is 24.50. At 20.41x, ANUHPHR trades at a 16.7% discount to sector peers.
Anuh Pharma Limited offers an Earnings Yield (E/P) of 4.96% and a PEG Ratio (Price/Earnings to Growth) of 4.80, reflecting the valuation relative to estimated EPS expansion trajectory.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.